Tamoxifen resistance in breast cancer elucidating mechanisms Taboo chat

tamoxifen resistance in breast cancer elucidating mechanisms-21

Here, we report that an important innate immune response kinase, the IκB kinase-related TANK-binding kinase 1 (TBK1), is a crucial determinant of resistance to tamoxifen therapies.

We show that TBK1 increases ERα transcriptional activity through phosphorylation modification of ERα at the Ser-305 site.

However, the exact role of TBK1 in breast cancer remains unclear.

Estrogen receptor α (ERα) is a nuclear receptor that exerts a profound influence on the initiation and progression of breast cancer by regulating cell transformation, proliferation, and metastasis (11–13).

Administration of BX795 in conjunction with tamoxifen achieved synergistic inhibitory effects on tumors.